Searched over 200M research papers
10 papers analyzed
These studies suggest thiazide or thiazide-like diuretics are the first drug of choice for hypertension.
19 papers analyzed
Hypertension, or high blood pressure, is a common condition that can lead to severe health complications if left untreated. The choice of the first-line drug for managing hypertension is crucial for reducing the risk of cardiovascular events, stroke, and mortality. This article synthesizes findings from multiple studies to determine the most effective first-line antihypertensive drug.
Thiazide diuretics, particularly low-dose thiazides, have been consistently shown to be highly effective as a first-line treatment for hypertension. They significantly reduce mortality, total cardiovascular events, stroke, and coronary heart disease compared to placebo or no treatment . For instance, low-dose thiazides reduced mortality (RR 0.89), total cardiovascular events (RR 0.70), stroke (RR 0.68), and coronary heart disease (RR 0.72).
When compared to other antihypertensive drug classes, thiazide diuretics often show superior or comparable effectiveness. Studies indicate that thiazides likely do not change total mortality but decrease some morbidity outcomes such as cardiovascular events and withdrawals due to adverse effects when compared to beta-blockers, calcium channel blockers, ACE inhibitors, and alpha-blockers. Additionally, thiazide diuretics have shown better primary effectiveness than ACE inhibitors in reducing the risk of acute myocardial infarction, hospitalization for heart failure, and stroke.
ACE inhibitors are another class of drugs used as first-line treatment for hypertension. They have been shown to reduce mortality, stroke, coronary heart disease, and total cardiovascular events . However, when compared directly to thiazide diuretics, ACE inhibitors are generally less effective in reducing heart failure and stroke.
Calcium channel blockers are also used as first-line agents and have been shown to reduce stroke and total cardiovascular events . However, their effectiveness in reducing coronary heart disease and mortality is less robust compared to thiazide diuretics.
Beta-blockers have been downgraded from their previous position as first-choice drugs for hypertension due to their relatively lower effectiveness in reducing mortality and cardiovascular events compared to thiazide diuretics and other drug classes . They are now often reserved for patients with specific comorbid conditions such as angina or post-myocardial infarction.
Other drug classes, such as alpha-blockers and angiotensin II receptor blockers (ARBs), have not shown significant advantages over thiazide diuretics in terms of reducing mortality and cardiovascular events .
Based on the comprehensive analysis of multiple studies, low-dose thiazide diuretics are the first drug of choice for treating hypertension. They have demonstrated superior effectiveness in reducing mortality, stroke, coronary heart disease, and total cardiovascular events compared to other antihypertensive drug classes. While ACE inhibitors and calcium channel blockers are also effective, the evidence supporting thiazide diuretics is more robust. Beta-blockers and other drug classes are generally less effective and are recommended for specific patient populations with comorbid conditions.
Most relevant research papers on this topic